BriaCell Therapeutics Corp., a clinical-stage biotechnology company developing novel immunotherapies, has been awarded New Zealand Patent No. 785587 titled "WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF." The patent provides exclusivity through February 27, 2037, and represents a significant milestone in the company's intellectual property strategy for personalized cancer immunotherapy.
Patent Technology and Precision Medicine Approach
The newly granted patent covers methods of selecting BriaCell's whole-cell cancer immunotherapy technology for subjects with cancer based on HLA allele profile matching. This approach supports the company's precision medicine strategy aimed at personalizing immunotherapy for improved patient outcomes by matching treatment selection to individual patient genetic profiles.
"We are thrilled that the New Zealand Patent Office recognized the innovative nature of BriaCell's novel whole cell immunotherapy and its potential therapeutic applications for cancer patients," said Dr. William V. Williams, President and CEO of BriaCell.
Strategic Patent Portfolio Development
The New Zealand patent award is part of BriaCell's broader strategy to establish a strong international patent portfolio that will enable the global development and commercialization of its immunotherapy platform across multiple cancer indications. This intellectual property protection is crucial for the company's ability to advance its whole-cell cancer vaccine technology through clinical development and eventual commercialization.
Company Profile and Technology Platform
BriaCell Therapeutics is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. The company's whole-cell immunotherapy platform represents an innovative approach to cancer treatment, utilizing patient-specific HLA matching to optimize therapeutic outcomes.
The patent protection extends through February 27, 2037, providing BriaCell with substantial market exclusivity for its HLA-matched whole-cell cancer vaccine selection methods in New Zealand. This timeline allows the company significant runway for clinical development, regulatory approval processes, and commercial launch activities in the New Zealand market.
